Home
Font Size:
1
2
3
Send to a Friend
Company
Mission
History
About Us
Awards
Contact
Driving Directions
Technology
Product Pipeline
MORAb-004
Farletuzumab
MORAb-009
Preclinical Pipeline
Clinical Trials
Farletuzumab
MORAb-004
MORAb-009
Partnerships
Research Alliances
News & Events
2010 News
2009 News Archive
2008 News Archive
2007 News Archive
2006 News Archive
2005 News Archive
2004 News Archive
2003 News Archive
2002 News Archive
2001 News Archive
Events
Careers
Current Job Openings
Our Work Environment
Benefits
2010 News
2009 News Archive
2008 News Archive
2007 News Archive
2006 News Archive
2005 News Archive
2004 News Archive
2003 News Archive
2002 News Archive
2001 News Archive
Events
2009 News Archive
Morphotek, Inc. Announces a Licensing Deal with Centocor Ortho Biotech Inc. for Exclusive Development and Commercialization Rights for a Therapeutic Monoclonal Antibody
October 28, 2009
...
+ Read the Article
Farletuzumab Data Presented on Phase II Clinical Trial in First-Relapsed Ovarian Cancer Subjects
September 24, 2009
...
+ Read the Article
Morphotek, Inc. Awarded Funding to Develop Therapeutic Antibodies Against Potential Biowarfare Toxins
September 23, 2009
...
+ Read the Article
Ovarian Cancer Patients Given True Gift of Happiness
August 25, 2009
...
+ Read the Article
Morphotek, Inc. and Cancer Innovations, Inc. Announce Evaluation and Option Agreement for Therapeutic Monoclonal Antibodies
July 15, 2009
...
+ Read the Article
Morphotek, Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
July 1, 2009
...
+ Read the Article
Morphotek, Inc. Announces FDA Acceptance of Investigational New Drug Application for MORAb-004, A Monoclonal Antibody for the Treatment of Cancer
June 9, 2009
...
+ Read the Article
Morphotek, Inc and Lonza Group LTD Enter Into Manufacturing Services Agreement
May 19, 2009
...
+ Read the Article
Human Genome Sciences and Morphotek, Inc. Announce Collaboration to Discover, Develop and Commercialize Antibodies for Oncology and Immunology
March 25, 2009
...
+ Read the Article
Morphotek, Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer
March 23, 2009
...
+ Read the Article
Go to Page:
1
2
Results per page
10
25
50